T. Köhnke

发表

Data mining for mutation-specific targets in acute myeloid leukemia

A. Gentles, R. Majeti, Daniel Thomas, 2019, Leukemia.

Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab

T. Knösel, M. Subklewe, J. Tischer, 2015, Journal of Hematology & Oncology.

Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML

W. Hiddemann, X. Liu, K. Metzeler, 2018, Leukemia.

Enasidenib drives human erythroid differentiation independently of isocitrate dehydrogenase 2.

R. Majeti, Y. Nakauchi, E. Gars, 2020, The Journal of clinical investigation.

Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism

W. Hiddemann, K. Metzeler, B. Vick, 2016, Leukemia.

Acetylsalicylic Acid Reduces the Severity of Dextran Sodium Sulfate-Induced Colitis and Increases the Formation of Anti-Inflammatory Lipid Mediators

K. Weylandt, M. Rothe, D. Baumgart, 2013, BioMed research international.

Targeting CD157 in AML using a novel, Fc-engineered antibody construct

W. Hiddemann, J. Terrett, C. Rohlff, 2017, Oncotarget.

Reduction of inflammation and chronic tissue damage by omega-3 fatty acids in fat-1 transgenic mice with pancreatitis.

K. Weylandt, J. Glickman, J. Kang, 2008, Biochimica et biophysica acta.

Integrated multiomic approach for identification of novel immunotherapeutic targets in AML

F. Herzog, Victor Solis-Mezarino, M. Subklewe, 2022, Biomarker research.

Response assessment in acute myeloid leukemia by flow cytometry supersedes cytomorphology at time of aplasia, amends cases without molecular residual disease marker and serves as an independent prognostic marker at time of aplasia and post-induction

W. Hiddemann, K. Metzeler, K. Spiekermann, 2019, Haematologica.

Early assessment of minimal residual disease in AML by flow cytometry during aplasia identifies patients at increased risk of relapse

E. Hoster, W. Hiddemann, S. Bohlander, 2014, Leukemia.

CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330.

W. Hiddemann, K. Metzeler, K. Spiekermann, 2014, Blood.

MYELOID NEOPLASIA CD 33 target validation and sustained depletion of AML blasts in long-term cultures by the bispeci fi c T-cell – engaging antibody AMG 330

W. Hiddemann, K. Metzeler, K. Spiekermann, 2013 .

Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia

W. Hiddemann, K. Metzeler, S. Bohlander, 2017, Leukemia.

A Combined Score of Minimal Residual Disease (MRD) Assessment by Flow Cytometry, Cytogenetic and Molecular Markers As Well As Age Predicts Outcome and Can Potentially Guide MRD-Based Therapy in Acute Myeloid Leukemia

W. Hiddemann, K. Spiekermann, J. Braess, 2011 .

Single-cell mutational profiling enhances the clinical evaluation of AML MRD.

Johannes G. Reiter, M. Liedtke, R. Majeti, 2020, Blood advances.

Virus infection in HLA-haploidentical hematopoietic stem cell transplantation: incidence in the context of immune recovery in two different transplantation settings

G. Ledderose, A. Moosmann, R. Reibke, 2015, Annals of Hematology.

Toll‐like receptor 7/8‐matured RNA‐transduced dendritic cells as post‐remission therapy in acute myeloid leukaemia: results of a phase I trial

W. Hiddemann, K. Spiekermann, A. Moosmann, 2020, Clinical & translational immunology.

Dysregulated Lipid Synthesis by Oncogenic IDH1 Mutation Is a Targetable Synthetic Lethal Vulnerability

A. Reinisch, R. Majeti, Manhong Wu, 2022, Cancer discovery.

Recent developments in immunotherapy of acute myeloid leukemia

M. Subklewe, Marion Subklewe, Felix S. Lichtenegger, 2017, Journal of Hematology & Oncology.

Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia

D. Bottomly, S. McWeeney, R. Majeti, 2020, Nature Cancer.

A Role for Lipid Mediators in Acute Myeloid Leukemia

K. Weylandt, A. Loew, Anne Pietzner, 2019, International journal of molecular sciences.

Asparaginase activities during intensified treatment with pegylated E. coli asparaginase in adults with newly-diagnosed acute lymphoblastic leukemia

C. Lanvers-Kaminsky, J. Boos, M. Eveslage, 2020, Leukemia & lymphoma.

The TRACE-Seq method tracks recombination alleles and identifies clonal reconstitution dynamics of gene targeted human hematopoietic stem cells

R. Majeti, M. Porteus, Ciaran M. Lee, 2021, Nature Communications.

TRACE-Seq Reveals Clonal Reconstitution Dynamics of Gene Targeted Human Hematopoietic Stem Cells

R. Majeti, M. Porteus, Ciaran M. Lee, 2020, bioRxiv.

Immunotherapy for Acute Myeloid Leukemia.

M. Subklewe, F. Lichtenegger, T. Köhnke, 2015, Seminars in hematology.

Diagnosis of CLL revisited: increased specificity by a modified five‐marker scoring system including CD200

W. Hiddemann, K. Spiekermann, Z. Pasalic, 2017, British journal of haematology.

Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse

E. Hoster, W. Hiddemann, S. Bohlander, 2014, Haematologica.

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells.

A. Reinisch, R. Majeti, T. Köhnke, 2023, Journal of visualized experiments : JoVE.

RUNX1 loss renders hematopoietic and leukemic cells dependent on IL-3 and sensitive to JAK inhibition

P. Khatri, A. Reinisch, R. Majeti, 2023, The Journal of clinical investigation.

Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia.

W. Hiddemann, K. Metzeler, K. Spiekermann, 2017, Leukemia.